Predictors of botulinum toxin type A response in patients with migraine: a meta-analysis
Abstract
ABSTRACT Background Migraine is one of the most common neurological diseases, imposing a heavy burden on society. Botulinum toxin type A (BT-A) has been approved as a safe and effective preventive treatment; however, not all patients report effectiveness after BT-A treatment. Thus, identifying BT-A responders in advance is valuable for treatment. Several studies have shown that some characteristics of headache, like a shorter disease duration and the absence of medication overuse, are potential predictors of clinical response. This meta-analysis aims to identify predictors linked to BT-A in people with migraine. Methods PubMed, Web of Science, Embase and the Cochrane Library were searched for studies. All cohort studies reporting the factors of responders and non-responders to BT-A injection were selected. Results Eleven studies met the criteria for selection. Of the 18 factors identified, only six were reported in at least three studies. BT-A response was associated with disease duration (MD: −2.37, CI: [−4.03, −0.83], p = 0.0002). In sensitivity analysis, the outcome of headache days was also statistically significant (MD: 1.02, CI: [0.45, 1.59], p = 0.0004). Conclusion The findings of this meta-analysis support disease duration and headache days as predictive factors of BT-A response in people with migraine. Injecting BT-A at an early stage might be beneficial for migraine patients. However, the predictors were based on a small number of studies; thus, more studies are…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.